2024
Association between thymectomy and incidence of renal cell carcinoma (RCC).
Barragan-Carrillo R, Ebrahimi H, Chawla N, Salgia N, Castro D, Chehrazi-Raffle A, Dizman N, Hsu J, Meza L, Zengin Z, LeVee A, Tripathi A, Dorff T, Bergerot C, Bergerot P, Eilber K, Dallas K, Pal S. Association between thymectomy and incidence of renal cell carcinoma (RCC). Journal Of Clinical Oncology 2024, 42: 371-371. DOI: 10.1200/jco.2024.42.4_suppl.371.Peer-Reviewed Original ResearchRenal cell carcinomaIncidence of nephrectomyIncidence of renal cell carcinomaMedian age of patientsFrequency of nephrectomyAge of patientsT cell productionProportion of patientsRate of nephrectomyFisher's exact testGeneral populationAge-matched populationICD-9/10 codesPopulation-based cohortPopulation-based studyImmunogenic cancerPrior thymectomyChi-square testCell carcinomaMedian ageSurgical interventionNephrectomyThymectomyExact testOSHPD database
2023
Changes in Perception of Cure Among Patients With Genitourinary Cancers Initiating Immune Checkpoint Inhibitors: A Longitudinal Study
Bergerot C, Philip E, Govindarajan A, Castro D, Malhotra J, Bergerot P, Salgia S, Salgia M, Salgia N, Hsu J, Meza L, Zengin Z, Liu S, Chehrazi-Raffle A, Tripathi A, Dorff T, Pal S. Changes in Perception of Cure Among Patients With Genitourinary Cancers Initiating Immune Checkpoint Inhibitors: A Longitudinal Study. Clinical Genitourinary Cancer 2023, 21: 626-630.e3. PMID: 37391301, PMCID: PMC11225089, DOI: 10.1016/j.clgc.2023.05.018.Peer-Reviewed Original ResearchConceptsPerception of cureExpectation of cureGenitourinary cancersImmune checkpoint inhibitor therapyCheckpoint inhibitor therapyImmune checkpoint inhibitorsProportion of patientsSevere side effectsLongitudinal studyChi-square testICI therapyCheckpoint inhibitorsInhibitor therapyECOG scoreGeneral linear modelingPatients' perceptionsMetastatic cancerPatientsSide effectsDecreased anxietyTherapyCancerCureLower ratesAnxiety Scale
2022
Changes in perception of immunotherapy over time among patients with advanced genitourinary cancers.
Malhotra J, Philip E, Govindarajan A, Meza L, Zengin Z, Salgia S, Muddasani R, Chawla N, Castro D, Chehrazi-Raffle A, Dizman N, Bergerot P, Hsu J, Dorff T, Pal S, Bergerot C. Changes in perception of immunotherapy over time among patients with advanced genitourinary cancers. Journal Of Clinical Oncology 2022, 40: 328-328. DOI: 10.1200/jco.2022.40.6_suppl.328.Peer-Reviewed Original ResearchAdvanced genitourinary cancersGenitourinary cancersExpectation of cureQuality of lifeSide effectsMetastatic genitourinary cancerProportion of patientsStart of therapyMajority of patientsMonths of treatmentRenal cell carcinomaSevere side effectsLongitudinal studyMedian ageClinical outcomesImmunotherapy treatmentCell carcinomaPatients' perceptionsImmunotherapyPatientsGreater efficacyTumor progressionCancerCancer treatmentTime points